Literature DB >> 35194172

CRISPR in cancer biology and therapy.

Alyna Katti1,2, Bianca J Diaz1,2, Christina M Caragine3,4, Neville E Sanjana5,6, Lukas E Dow7,8.   

Abstract

Over the past decade, CRISPR has become as much a verb as it is an acronym, transforming biomedical research and providing entirely new approaches for dissecting all facets of cell biology. In cancer research, CRISPR and related tools have offered a window into previously intractable problems in our understanding of cancer genetics, the noncoding genome and tumour heterogeneity, and provided new insights into therapeutic vulnerabilities. Here, we review the progress made in the development of CRISPR systems as a tool to study cancer, and the emerging adaptation of these technologies to improve diagnosis and treatment.
© 2022. Springer Nature Limited.

Entities:  

Mesh:

Year:  2022        PMID: 35194172     DOI: 10.1038/s41568-022-00441-w

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN: 1474-175X            Impact factor:   60.716


  319 in total

1.  Intervening sequences of regularly spaced prokaryotic repeats derive from foreign genetic elements.

Authors:  Francisco J M Mojica; César Díez-Villaseñor; Jesús García-Martínez; Elena Soria
Journal:  J Mol Evol       Date:  2005-02       Impact factor: 2.395

2.  CRISPR provides acquired resistance against viruses in prokaryotes.

Authors:  Rodolphe Barrangou; Christophe Fremaux; Hélène Deveau; Melissa Richards; Patrick Boyaval; Sylvain Moineau; Dennis A Romero; Philippe Horvath
Journal:  Science       Date:  2007-03-23       Impact factor: 47.728

3.  Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease.

Authors:  Seung Woo Cho; Sojung Kim; Jong Min Kim; Jin-Soo Kim
Journal:  Nat Biotechnol       Date:  2013-01-29       Impact factor: 54.908

4.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.

Authors:  Hyuna Sung; Jacques Ferlay; Rebecca L Siegel; Mathieu Laversanne; Isabelle Soerjomataram; Ahmedin Jemal; Freddie Bray
Journal:  CA Cancer J Clin       Date:  2021-02-04       Impact factor: 508.702

5.  CRISPR elements in Yersinia pestis acquire new repeats by preferential uptake of bacteriophage DNA, and provide additional tools for evolutionary studies.

Authors:  C Pourcel; G Salvignol; G Vergnaud
Journal:  Microbiology (Reading)       Date:  2005-03       Impact factor: 2.777

6.  Clustered regularly interspaced short palindrome repeats (CRISPRs) have spacers of extrachromosomal origin.

Authors:  Alexander Bolotin; Benoit Quinquis; Alexei Sorokin; S Dusko Ehrlich
Journal:  Microbiology       Date:  2005-08       Impact factor: 2.777

7.  Multiplex genome engineering using CRISPR/Cas systems.

Authors:  Le Cong; F Ann Ran; David Cox; Shuailiang Lin; Robert Barretto; Naomi Habib; Patrick D Hsu; Xuebing Wu; Wenyan Jiang; Luciano A Marraffini; Feng Zhang
Journal:  Science       Date:  2013-01-03       Impact factor: 47.728

8.  RNA-guided human genome engineering via Cas9.

Authors:  Prashant Mali; Luhan Yang; Kevin M Esvelt; John Aach; Marc Guell; James E DiCarlo; Julie E Norville; George M Church
Journal:  Science       Date:  2013-01-03       Impact factor: 47.728

9.  RNA-programmed genome editing in human cells.

Authors:  Martin Jinek; Alexandra East; Aaron Cheng; Steven Lin; Enbo Ma; Jennifer Doudna
Journal:  Elife       Date:  2013-01-29       Impact factor: 8.140

Review 10.  The CRISPR tool kit for genome editing and beyond.

Authors:  Mazhar Adli
Journal:  Nat Commun       Date:  2018-05-15       Impact factor: 14.919

View more
  8 in total

Review 1.  Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021.

Authors:  Qing Wu; Wei Qian; Xiaoli Sun; Shaojie Jiang
Journal:  J Hematol Oncol       Date:  2022-10-08       Impact factor: 23.168

Review 2.  CRISPR/Cas9: A revolutionary genome editing tool for human cancers treatment.

Authors:  Fatima Akram; Ikram Ul Haq; Sania Sahreen; Narmeen Nasir; Waqas Naseem; Memoona Imitaz; Amna Aqeel
Journal:  Technol Cancer Res Treat       Date:  2022 Jan-Dec

Review 3.  Large-Scale Chromatin Rearrangements in Cancer.

Authors:  Kosuke Yamaguchi; Xiaoying Chen; Asami Oji; Ichiro Hiratani; Pierre-Antoine Defossez
Journal:  Cancers (Basel)       Date:  2022-05-12       Impact factor: 6.575

4.  Influence of Electroporation Medium on Delivery of Cell-Impermeable Small Molecules by Electrical Short-Circuiting via an Aqueous Droplet in Dielectric Oil: A Comparison of Different Fluorescent Tracers.

Authors:  Yuki Watanabe; Hirohito Nihonyanagi; Rika Numano; Takayuki Shibata; Kazunori Takashima; Hirofumi Kurita
Journal:  Sensors (Basel)       Date:  2022-03-24       Impact factor: 3.576

5.  NF-kB (p50/p65)-Mediated Pro-Inflammatory microRNA (miRNA) Signaling in Alzheimer's Disease (AD).

Authors:  Walter J Lukiw
Journal:  Front Mol Neurosci       Date:  2022-06-28       Impact factor: 6.261

Review 6.  Therapeutic Potential of Intrabodies for Cancer Immunotherapy: Current Status and Future Directions.

Authors:  Thomas Böldicke
Journal:  Antibodies (Basel)       Date:  2022-07-18

Review 7.  Stimuli-responsive nanoformulations for CRISPR-Cas9 genome editing.

Authors:  Tianxu Fang; Xiaona Cao; Mysha Ibnat; Guojun Chen
Journal:  J Nanobiotechnology       Date:  2022-08-02       Impact factor: 9.429

Review 8.  Improving cancer immunotherapy by rationally combining oncolytic virus with modulators targeting key signaling pathways.

Authors:  Zhi Zhu; A J Robert McGray; Weijian Jiang; Binfeng Lu; Pawel Kalinski; Zong Sheng Guo
Journal:  Mol Cancer       Date:  2022-10-12       Impact factor: 41.444

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.